Lord, Abbett & Co
SNDX icon

Lord, Abbett & Co’s Syndax Pharmaceuticals SNDX Stock Holding History

Lord, Abbett & Co’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-212,967
Closed -$3.09M – 582
2023
Q3 		$3.09M Sell
212,967
-152,205
-42% -$2.88M 0.01% 506
2023
Q2 		$7.64M Sell
365,172
-119,494
-25% -$2.49M 0.03% 442
2023
Q1 		$10.2M Buy
484,666
+148,670
+44% +$3.7M 0.04% 412
2022
Q4 		$8.55M Buy
335,996
+1,033
+0.3% +$24.1K 0.03% 440
2022
Q3 		$8.05M Buy
334,963
+20,049
+6% +$450K 0.03% 428
2022
Q2 		$6.06M Buy
314,914
+21,565
+7% +$359K 0.02% 469
2022
Q1 		$5.1M Buy
293,349
+5,297
+2% +$89.2K 0.01% 545
2021
Q4 		$6.3M Sell
288,052
-2,792
-1% -$51.6K 0.01% 533
2021
Q3 		$5.56M Sell
290,844
-3,765
-1% -$62.7K 0.01% 585
2021
Q2 		$5.06M Buy
+294,609
New +$5.4M 0.01% 609

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Lord, Abbett & Co's SNDX Position: Q4 2023 in Review

Lord, Abbett & Co sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 212,967 shares — an estimated $3.09M sold.

Lord, Abbett & Co first reported a position in SNDX in Q2 2021 and held it in 10 quarters. The position peaked at $10.2M in Q1 2023. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

  • Lord, Abbett & Co reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 212,967 Syndax Pharmaceuticals shares in Q4 2023, an estimated $3.09M.
  • Lord, Abbett & Co first reported a position in Syndax Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • Lord, Abbett & Co's Syndax Pharmaceuticals position peaked at $10.2M in Q1 2023.
  • 177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Lord, Abbett & Co's 13F filing for Q4 2023, filed 12 Feb 2024.